Pain Research and Treatment / 2017 / Article / Tab 3 / Research Article
Evaluating the Measurement Properties of the Self-Assessment of Treatment Version II, Follow-Up Version, in Patients with Painful Diabetic Peripheral Neuropathy Table 3 (a) Convergent validity: correlations
between SAT II follow-up version and PRO measures at week 8. (b) Convergent validity: correlations
between SAT II follow-up version and PRO measures at week 12.
(a) Measures SAT II scores Pain improvement Impact summary Treatment continuation Treatment comparison BPI-DN item 5 −0.55 −0.46 −0.30 −0.51 BPI-DN item 5 change from baseline −0.60 −0.54 −0.40 −0.60 BPI-DN item 9F −0.42 −0.34 −0.22 −0.40 BPI-DN item 9F change from baseline −0.55 −0.55 −0.35 −0.61 HADS anxiety subscale −0.10 −0.07 −0.09 −0.12 HADS anxiety subscale change from baseline −0.08 −0.09 −0.09 −0.10 HADS depression subscale −0.11 −0.10 −0.10 −0.11 HADS depression subscale change from baseline −0.13 −0.13 −0.14 −0.19 PGIC −0.79 −0.76 −0.57 −0.78 EQ-5D index 0.30 0.26 0.22 0.30 EQ-5D index change from baseline 0.32 0.31 0.30 0.38 EQ-5D VAS 0.20 0.16 0.16 0.19 EQ-5D VAS change from baseline 0.19 0.19 0.15 0.17
(b) Measures SAT II scores Pain improvement Impact summary Treatment continuation Treatment comparison BPI-DN item 5 −0.54 −0.42 −0.29 −0.39 BPI-DN item 5 change from baseline −0.58 −0.52 −0.42 −0.47 BPI-DN item 9F −0.42 −0.31 −0.21 −0.35 BPI-DN item 9F change from baseline −0.53 −0.49 −0.36 −0.47 HADS anxiety subscale −0.10 −0.06 −0.08 −0.12 HADS anxiety subscale change from baseline −0.06 −0.10 −0.04 −0.06 HADS depression subscale −0.09 −0.09 −0.09 −0.11 HADS depression subscale change from baseline −0.12 −0.18 −0.13 −0.14 PGIC −0.77 −0.74 −0.57 −0.74 EQ-5D index 0.30 0.28 0.18 0.23 EQ-5D index change from baseline 0.27 0.30 0.27 0.24 EQ-5D VAS 0.23 0.24 0.20 0.25 EQ-5D VAS change from baseline 0.20 0.23 0.21 0.22
